AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...

AstraZeneca said on Wednesday its China president Leon Wang had been detained by Chinese authorities and, although it did not ...

The company believes Chinese authorities are probing allegations that two current and two former employees had illegally ...

As of Friday's close, AstraZeneca's stock was down 6.6% since the start of 2024 and about 1.85% over the last 12 months. WHAT TO WATCH --PIPELINE: Market watchers will closely monitor the potential of ...

Key Takeaways Zacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture ...

BMO Capital Markets analyst Etzer Darout in a note to investors said the insurance fraud probe represents a “headline risk” ...

AstraZeneca Plc said its experimental obesity pill was well-tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines.

AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps.

AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...

Number of Hedge Fund Holders: 49 AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company, which focuses on the discovery, ...

AstraZeneca plans to hire over 800 in Singapore for engineering, quality, technical services, and supply chain roles at its ...